TVTX

Travere Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · travere.com

$44.91

After hrs $44.69 -0.25%

Mkt Cap $4.1B

52w Low $13.88 98.4% of range 52w High $45.43

50d MA $32.30 200d MA $28.77

P/E (TTM) -78.8x

EV/EBITDA 164.0x

P/B 34.3x

Debt/Equity 2.9x

ROE -22.2%

P/FCF 90.2x

RSI (14) —

ATR (14) —

Beta 0.87

50d MA $32.30

200d MA $28.77

Avg Volume 1.8M

About

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients wit…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 4, 2026	AMC	-0.24	-0.40	-65.3%	—	—	—	—	—	—	—	—
Feb 19, 2026	AMC	0.03	0.03	+0.0%	29.30	+0.6%	+3.7%	+4.9%	+5.4%	+0.1%	+1.4%	—
Oct 30, 2025	AMC	-0.31	0.28	+190.3%	29.65	+16.7%	+18.6%	+16.5%	+15.1%	+13.7%	+12.3%	—
Aug 6, 2025	AMC	-0.28	-0.14	+50.0%	17.24	+1.0%	-1.9%	-1.7%	+0.2%	+1.0%	+4.7%	—
May 1, 2025	AMC	-0.55	-0.47	+14.5%	20.76	+1.6%	+1.9%	+3.1%	-3.9%	-2.6%	-1.5%	—
Feb 20, 2025	AMC	-0.58	-0.73	-25.9%	23.58	-8.8%	-6.8%	-10.0%	-12.4%	-10.8%	-12.5%	—
Oct 31, 2024	AMC	-0.70	-0.70	+0.0%	17.50	+2.6%	+0.4%	+3.4%	+1.4%	-1.1%	+0.9%	—
Aug 1, 2024	AMC	-0.87	-0.90	-3.4%	9.24	+8.4%	-2.6%	-7.7%	-3.7%	-8.9%	-7.7%	—
May 6, 2024	AMC	-0.98	-1.76	-79.6%	6.55	+13.0%	+3.1%	+4.1%	+0.8%	-3.8%	-3.2%	—
Feb 15, 2024	AMC	-1.27	-1.16	+8.7%	8.74	+0.7%	-6.2%	-5.3%	-9.8%	-10.1%	-9.2%	—
Nov 7, 2023	AMC	-1.09	-1.17	-7.3%	7.18	+0.7%	-11.8%	-24.2%	-22.3%	-20.6%	-15.2%	—
Aug 3, 2023	AMC	-1.16	-1.13	+2.6%	16.28	-4.0%	-4.7%	-5.5%	-4.8%	-6.3%	-3.7%	—
May 4, 2023	AMC	-1.18	-1.27	-7.6%	15.97	+0.1%	+5.2%	+4.8%	+3.8%	+1.9%	+1.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 24	Guggenheim	Maintains	Buy → Buy	—	$40.82	$41.35	+1.3%	-0.8%	-0.0%	+0.2%	-1.8%	+3.2%
Apr 14	Guggenheim	Maintains	Buy → Buy	—	$30.70	$41.53	+35.3%	+37.2%	+33.4%	+28.8%	+32.8%	+31.2%
Apr 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$30.70	$41.53	+35.3%	+37.2%	+33.4%	+28.8%	+32.8%	+31.2%
Apr 14	Citigroup	Maintains	Buy → Buy	—	$30.70	$41.53	+35.3%	+37.2%	+33.4%	+28.8%	+32.8%	+31.2%
Apr 14	Canaccord Genuity	Maintains	Buy → Buy	—	$30.70	$41.53	+35.3%	+37.2%	+33.4%	+28.8%	+32.8%	+31.2%
Apr 14	Wedbush	Maintains	Outperform → Outperform	—	$30.70	$41.53	+35.3%	+37.2%	+33.4%	+28.8%	+32.8%	+31.2%
Mar 25	JP Morgan	Maintains	Overweight → Overweight	—	$26.79	$26.84	+0.2%	+2.9%	+4.2%	+1.7%	+3.2%	+10.9%
Feb 6	Piper Sandler	Maintains	Neutral → Neutral	—	$29.47	$29.91	+1.5%	+0.8%	+2.0%	+2.9%	+2.5%	+3.8%
Nov 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$36.26	$36.87	+1.7%	-2.3%	-3.0%	-6.3%	-3.9%	-2.6%
Nov 4	Piper Sandler	Maintains	Neutral → Neutral	—	$34.53	$33.99	-1.6%	-1.2%	-2.3%	-3.6%	-6.3%	-0.4%
Oct 31	TD Cowen	Maintains	Buy → Buy	—	$29.65	$34.60	+16.7%	+18.6%	+16.5%	+15.1%	+13.7%	+12.3%
Sep 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.19	$24.34	+0.6%	+2.7%	+5.1%	+0.2%	+0.9%	+1.7%
Sep 12	Stifel	Maintains	Hold → Hold	—	$25.00	$24.77	-0.9%	-6.1%	-8.0%	-8.9%	-5.4%	-3.2%
Sep 11	Wells Fargo	Maintains	Overweight → Overweight	—	$27.31	$27.71	+1.5%	-8.5%	-14.1%	-15.7%	-16.6%	-13.4%
Sep 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.64	$25.31	+17.0%	+26.2%	+15.5%	+8.5%	+6.3%	+5.2%
Sep 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.15	$18.20	+0.3%	+8.0%	+16.5%	+19.2%	+16.8%	+19.2%
Aug 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.44	$19.30	+10.7%	+1.5%	+0.3%	+4.1%	+12.4%	+21.3%
Aug 7	Wedbush	Maintains	Outperform → Outperform	—	$17.24	$17.41	+1.0%	-1.9%	-1.7%	+0.2%	+1.0%	+4.7%
Aug 7	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$17.24	$17.41	+1.0%	-1.9%	-1.7%	+0.2%	+1.0%	+4.7%
Jun 11	Citigroup	Maintains	Buy → Buy	—	$15.13	$15.31	+1.2%	-4.0%	-1.3%	-4.2%	-3.0%	-6.9%
May 16	Wedbush	Maintains	Outperform → Outperform	—	$21.15	$18.01	-14.8%	-20.6%	-19.6%	-17.0%	-21.5%	-25.8%
May 2	Wedbush	Maintains	Outperform → Outperform	—	$20.76	$21.09	+1.6%	+1.9%	+3.1%	-3.9%	-2.6%	-1.5%
May 2	Stifel	Maintains	Hold → Hold	—	$20.76	$21.09	+1.6%	+1.9%	+3.1%	-3.9%	-2.6%	-1.5%
Apr 23	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$15.88	$16.23	+2.2%	+5.2%	+11.0%	+15.4%	+21.9%	+26.4%
Apr 14	Guggenheim	Maintains	Buy → Buy	—	$14.50	$14.95	+3.1%	+2.3%	+2.8%	+0.5%	+2.9%	+4.2%
Apr 10	Canaccord Genuity	Maintains	Buy → Buy	—	$14.35	$14.50	+1.0%	-6.0%	+1.0%	+3.3%	+3.9%	+1.5%
Apr 3	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$17.94	$16.65	-7.2%	-7.7%	-16.4%	-15.4%	-21.1%	-20.0%
Apr 1	BofA Securities	Maintains	Buy → Buy	—	$17.92	$18.16	+1.3%	-2.7%	+0.1%	-7.6%	-16.4%	-15.3%
Feb 26	JP Morgan	Maintains	Overweight → Overweight	—	$20.65	$21.17	+2.5%	+1.8%	-0.0%	+3.6%	-4.1%	-4.6%
Feb 24	Citigroup	Maintains	Buy → Buy	—	$21.98	$22.06	+0.4%	-3.4%	-6.1%	-4.3%	-6.1%	-2.6%
Feb 21	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$23.58	$21.50	-8.8%	-6.8%	-10.0%	-12.4%	-10.8%	-12.5%
Feb 12	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$23.75	$23.53	-0.9%	-2.3%	-0.1%	-3.5%	-4.6%	-1.8%
Feb 12	Canaccord Genuity	Maintains	Buy → Buy	—	$23.75	$23.53	-0.9%	-2.3%	-0.1%	-3.5%	-4.6%	-1.8%
Feb 12	Evercore ISI	Maintains	Outperform → Outperform	—	$23.75	$23.53	-0.9%	-2.3%	-0.1%	-3.5%	-4.6%	-1.8%
Jan 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.07	$17.54	+2.8%	+5.9%	+8.2%	+7.6%	+14.0%	+14.0%
Nov 14	Piper Sandler	Maintains	Neutral → Neutral	—	$18.56	$18.65	+0.5%	-0.5%	-4.5%	-6.3%	-6.3%	-3.8%
Nov 1	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$17.50	$17.95	+2.6%	+0.4%	+3.4%	+1.4%	-1.1%	+0.9%
Nov 1	Barclays	Maintains	Overweight → Overweight	—	$17.50	$17.95	+2.6%	+0.4%	+3.4%	+1.4%	-1.1%	+0.9%
Oct 21	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$17.87	$19.12	+7.0%	+1.3%	+0.6%	+0.5%	+1.2%	-1.9%
Oct 11	Leerink Partners	Maintains	Outperform → Outperform	—	$17.11	$17.05	-0.4%	-4.1%	+1.9%	+3.4%	+5.5%	+6.7%
Oct 9	BofA Securities	Maintains	Buy → Buy	—	$15.21	$15.65	+2.9%	+15.6%	+12.5%	+7.9%	+14.7%	+16.3%
Oct 9	Wedbush	Maintains	Outperform → Outperform	—	$15.21	$15.65	+2.9%	+15.6%	+12.5%	+7.9%	+14.7%	+16.3%
Oct 9	Guggenheim	Maintains	Buy → Buy	—	$15.21	$15.65	+2.9%	+15.6%	+12.5%	+7.9%	+14.7%	+16.3%
Oct 8	Leerink Partners	Maintains	Outperform → Outperform	—	$15.26	$15.31	+0.3%	-0.3%	+15.3%	+12.1%	+7.5%	+14.3%
Oct 1	Barclays	Maintains	Overweight → Overweight	—	$13.99	$13.74	-1.8%	+0.0%	-0.9%	-2.4%	+8.9%	+9.1%
Sep 30	Canaccord Genuity	Maintains	Buy → Buy	—	$14.01	$14.30	+2.1%	-0.1%	-0.1%	-1.0%	-2.6%	+8.7%
Sep 27	BofA Securities	Maintains	Buy → Buy	—	$15.04	$14.18	-5.7%	-6.8%	-7.0%	-7.0%	-7.8%	-9.2%
Sep 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.04	$14.18	-5.7%	-6.8%	-7.0%	-7.0%	-7.8%	-9.2%
Sep 27	Guggenheim	Maintains	Buy → Buy	—	$15.04	$14.18	-5.7%	-6.8%	-7.0%	-7.0%	-7.8%	-9.2%
Sep 27	Citigroup	Maintains	Buy → Buy	—	$15.04	$14.18	-5.7%	-6.8%	-7.0%	-7.0%	-7.8%	-9.2%

Recent Filings

8-K · 2.02 !! High

Travere Therapeutics, Inc. -- 8-K 2.02: Earnings Results

Travere Therapeutics reported earnings results, with detailed financial performance metrics available in the attached press release exhibit for investor review.

May 4

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

TVTX's FILSPARI demonstrated superior efficacy in reducing proteinuria (48% vs 27%) in IgA nephropathy patients, validating its lead program and strengthening approval prospects for this high-value kidney disease indication.

Apr 14

8-K

Travere Therapeutics, Inc. -- 8-K Filing

Travere Therapeutics' FILSPARI achieved $103 million in Q4 2025 net sales with 108% year-over-year growth and 908 new patient starts, demonstrating strong market adoption for this rare disease treatment.

Feb 19

Data updated apr 27, 2026 6:09am · Source: massive.com